Stock TSHA TAYSHA GENE THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Real-time Estimate Cboe BZX
Other stock markets
 18:06:30 03/05/2024 BST 		5-day change 1st Jan Change
2.615 USD +1.36% Intraday chart for Taysha Gene Therapies, Inc. +8.16% +46.05%
05-02 Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome CI
04-09 Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply
US Futures Flat in Wednesday's Premarket as Investors Await Fed's Interest Rate Decision
Top Premarket Gainers
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
Taysha Gene Therapies Gets Expanded Eligibility in Canada for Early Trial of Rett Syndrome Treatment
Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
Taysha Gene Therapies Insider Bought Shares Worth $163,000, According to a Recent SEC Filing
Taysha Gene Therapies Q3 Net Loss Widens Unexpectedly
Taysha Gene Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Taysha Gene Says New Preclinical Data Reinforce TSHA-102 Potential to Address Rett Syndrome Root Cause; Shares Rise
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy 30th Annual Congress
Pliant Therapeutics Appoints Chief Regulatory Officer
Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Taysha to End TSHA-120 Program in Giant Axonal Neuropathy; Shares Down After-Hours
Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy
Top Midday Gainers
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSHA Stock
  4. News Taysha Gene Therapies, Inc.
  5. Other languages